All In Biotech

Drug Trial Radar · NCT07222800

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Dec 11, 2025

Primary completion

Feb 23, 2030

Study completion Aug 17, 2031

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have colorectal cancer that has spread to other parts of your body. * Be in good enough health to receive study treatment. * Should not be pregnant before starting treatment. Participants will be randomized (like flipping a coin) to one of 2 different treatment arms. The first arm (Arm A) will include the new medicine PF-08634404 in combination with chemotherapy that is approved for colorectal cancer, and the second arm (Arm B) will include an approved medicine for colorectal cancer, called Bevacizumab, in combination with chemotherapy that is approved for this type of cancer. Participants and their doctors will not know which arm they are being assigned to. Participants will receive all the study medications through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, and participants may continue receiving it if it is helping and they are not experiencing serious side effects. The medicine will be given at a clinical site, where trained medical staff will check participants during and after each treatment. * The study is expected to last approximately 33 months for each participant. * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will return for a final visit about 30 to37 days later to check their health and review any side effects. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records to check on health status and any new treatments.

Conditions

  • Intestinal Neoplasms
  • Gastrointestinal Neoplasms
  • Digestive System Neoplasms
  • Neoplasms by Site
  • Digestive System Diseases
  • Gastrointestinal Diseases
  • Colonic Diseases
  • Intestinal Diseases
  • Rectal Diseases
  • Colorectal Neoplasms

Interventions

  • PF-08634404Drug

    Solution for infusion

  • BevacizumabBiological

    Injection for intravenous use

  • ChemotherapyDrug

    Injection for intravenous use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)Time frame: Approximately 4 years
  2. Overall survival (OS)Time frame: Approximately 4 years

Locations

372 sites in 17 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers

    Chandler, Arizona · Recruiting

  • Banner Gateway Medical Center

    Gilbert, Arizona · Not yet recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Not yet recruiting

  • Ironwood Cancer & Research Centers

    Gilbert, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Glendale, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Goodyear, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Mesa, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Mesa, Arizona · Recruiting

  • Banner MD Anderson Cancer Center at Banner University Medical Center- Phoenix

    Phoenix, Arizona · Not yet recruiting

  • Banner MD Anderson Cancer Center

    Phoenix, Arizona · Not yet recruiting

  • Banner University Medical Center Phoenix

    Phoenix, Arizona · Not yet recruiting

  • Ironwood Cancer & Research Centers

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Building- Phoenix

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Hospital

    Phoenix, Arizona · Recruiting

  • Mayo Clinic

    Scottsdale, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Scottsdale, Arizona · Recruiting

  • Banner Boswell Medical Center

    Sun City, Arizona · Not yet recruiting

  • Banner MD Anderson Cancer Center

    Sun City, Arizona · Not yet recruiting

  • BMDACC Boswell

    Sun City, Arizona · Not yet recruiting

  • Highlands Oncology Group

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • UCSF at Berkeley Outpatient Center

    Berkeley, California · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus Comprehensive Cancer Center

    Berkeley, California · Recruiting

  • UCSD Medical Center - Encinitas

    Encinitas, California · Recruiting

  • Palo Alto Medical Foundation - Fremont Center

    Fremont, California · Recruiting

  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

    La Jolla, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • UCSD Koman Family Outpatient Pavilion

    La Jolla, California · Recruiting

  • Palo Alto Medical Foundation - Palo Alto Center

    Palo Alto, California · Recruiting

  • Roseville Medical Plaza Care Center

    Roseville, California · Recruiting

  • Sutter Medical Center, Sacramento Infusion Center at Roseville

    Roseville, California · Recruiting

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • University of California, Davis Medical Center

    Sacramento, California · Recruiting

  • UC San Diego McGrath Outpatient Pavilion - Hillcrest

    San Diego, California · Recruiting

  • UC San Diego Medical Center - Hillcrest

    San Diego, California · Recruiting

  • UC San Diego Medical Center - Rancho Bernardo

    San Diego, California · Recruiting

  • UCSF at China Basin

    San Francisco, California · Recruiting

  • UCSF at Mount Zion

    San Francisco, California · Recruiting

  • UCSF at Parnassus

    San Francisco, California · Recruiting

Showing 40 of 372 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.